Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OlaReDo: Olaratumab and Doxorubicin Rechallenge in STS
NCT03698227Phase 2Terminated
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Nov 2018
- Primary completion
- Jun 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of olaratumab in soft tissue sarcoma (STS), sponsored by Institut für Klinische Krebsforschung. Started Nov 2018; status: terminated.
02
Drugs
olaratumab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03698227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03698227.